NanoString Technologies Inc. Maneuvers in Line for $86 Million IPO
5/21/2013 7:55:32 AM
More...
|
NanoString Technologies Inc. Announces Oral Study Presentation of the Prosigna™ Assay in Postmenopausal Node-Positive Breast Cancer at the 2013 Annual American Society of Clinical Oncology
5/16/2013 8:44:06 AM
More...
|
NanoString Technologies Inc. Secures Option From the Broad Institute for Exclusive Worldwide License of Liver Cancer Gene Signature
4/17/2013 11:22:50 AM
More...
|
NanoString Technologies Inc. Presents Positive Results From Multisite Analytical Validation Study of Prosigna™ Breast Cancer
3/6/2013 8:23:01 AM
More...
|
NanoString Technologies Inc. Expands Leadership Team With the Hiring of Two Seasoned Executives
2/28/2013 6:31:34 AM
More...
|
NanoString Technologies Inc. Launches Its First Commercial Diagnostic Product in the European Union and Israel
2/19/2013 9:31:45 AM
More...
|
NanoString Technologies Inc. Announces Positive Results From Second Validation Study of PAM50-based Breast Cancer Assay
12/6/2012 11:29:15 AM
More...
|
NanoString Technologies Inc. Completes $15.3 Million Series E Financing
12/3/2012 7:23:39 AM
More...
|
Fluidigm Corporation Files Lawsuit Against NanoString Technologies Inc.'s Deceptive Marketing
11/8/2012 10:18:42 AM
More...
|
NanoString Technologies Inc. Appoints James A. Johnson as Chief Financial Officer
10/3/2012 10:10:50 AM
More...
|
|